NATCOPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.1
| Stock Code | NATCOPHARM | Market Cap | 15,824 Cr. | Current Price | 884 ₹ | High / Low | 1,227 ₹ |
| Stock P/E | 12.4 | Book Value | 478 ₹ | Dividend Yield | 0.68 % | ROCE | 16.6 % |
| ROE | 16.1 % | Face Value | 2.00 ₹ | DMA 50 | 1,000 ₹ | DMA 200 | 969 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 210 Cr. | PAT Prev Qtr | 107 Cr. |
| RSI | 34.3 | MACD | -66.5 | Volume | 9,83,540 | Avg Vol 1Wk | 8,55,220 |
| Low price | 789 ₹ | High price | 1,227 ₹ | PEG Ratio | 0.45 | Debt to equity | 0.08 |
| 52w Index | 21.6 % | Qtr Profit Var | -51.0 % | EPS | 71.6 ₹ | Industry PE | 32.1 |
📊 Analysis: NATCOPHARM presents solid fundamentals with ROE at 16.1% and ROCE at 16.6%, supported by a low debt-to-equity ratio of 0.08. EPS of 71.6 ₹ and PAT growth (210 Cr. vs 107 Cr.) highlight profitability recovery. Valuation is attractive with P/E at 12.4 compared to industry average of 32.1, and PEG ratio at 0.45 suggests undervaluation relative to growth. Dividend yield of 0.68% provides modest income. Technicals show weakness (RSI 34.3, MACD -66.5), indicating oversold conditions and short-term bearish sentiment, but long-term fundamentals remain strong.
💡 Entry Zone: Ideal entry lies between ₹820 – ₹880, closer to recent support levels and below DMA 50 (1,000 ₹), offering valuation comfort.
⏳ Exit / Holding Strategy: Existing holders should maintain a long-term horizon (3–5 years) given undervaluation, strong fundamentals, and low debt. Consider partial profit booking near ₹1,150–1,200 resistance zone. Exit fully only if earnings momentum weakens or valuations stretch without growth support.
Positive
- ✅ Attractive valuation (P/E 12.4 vs industry 32.1)
- ✅ Strong EPS (71.6 ₹) and PAT recovery
- ✅ Low debt-to-equity ratio (0.08) ensures financial stability
- ✅ PEG ratio of 0.45 indicates undervaluation relative to growth
Limitation
- ⚠️ Technical weakness (RSI oversold, MACD negative)
- ⚠️ Dividend yield at 0.68% is modest
- ⚠️ Quarterly profit variation (-51%) highlights volatility
Company Negative News
- 📉 Short-term technical weakness with RSI at 34.3
- 📉 Volatile quarterly profit variation (-51%)
Company Positive News
- 📈 PAT recovery to 210 Cr. from 107 Cr.
- 📈 FII holdings increased (+2.21%), showing foreign investor confidence
- 📈 DII holdings stable (+0.07%)
Industry
- 🏭 Industry P/E at 32.1 highlights NATCOPHARM’s undervaluation
- 🏭 Pharma sector benefits from rising demand for generics and specialty drugs
Conclusion
🔎 NATCOPHARM is a fundamentally strong pharma company trading at attractive valuations. Best suited for accumulation near ₹820–₹880. Hold for 3–5 years, booking profits near resistance levels, while monitoring earnings consistency and technical recovery.
Would you like me to expand this into a sector overlay comparing NATCOPHARM with other pharma peers, or a growth drivers analysis highlighting catalysts like generics expansion and export opportunities?